Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates
- 1 December 2018
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 24 (14), 1843-1851
- https://doi.org/10.1177/1352458517735191
Abstract
Background: Population-based studies on neuromyelitis optica spectrum disorders (NMOSD) are limited, and it is unclear whether the rates have changed with the implementation of the new 2015 criteria. Objectives: To estimate the incidence and prevalence of NMOSD in Catalonia (Spain), using both the 2006 and the 2015 criteria. Methods: In this clinic-based retrospective study, patients diagnosed with NMOSD between 2006 and 2015 were identified using multiple sources, including direct contact to all Catalan hospitals, identification of cases through the Catalan Health Surveillance System, and registry of antibodies to aquaporin-4 (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG-IgG) in a reference laboratory. The incidence rate was calculated for the period 1 January 2006-1 January 2016 and prevalence for the date 1 January 2016. Results: We identified 74 patients (by the 2015 criteria). Most patients were Caucasian (81%), and female (76%) with a median age at disease onset of 42 years (range, 10-76 years). In total, 54 (73%) patients were positive for AQP4-IgG, 11 (15%) double-seronegative, and 9 (12%) MOG-IgG-positive. Rates of incidence and prevalence (0.63/1,000,000 person-years and 0.89/100,000, respectively) were 1.5-fold higher than those reported by the 2006 criteria. Lowest rates were seen in children and elder people and highest in women and middle-aged people (40-59 years). The female predominance was lost in incident AQP4-IgG-seronegative children and AQP4-IgG-positive elder people. MOG-IgG and double-seronegativity contributed similarly but did not influence the long-term outcome. Conclusion: The new criteria increase the estimates, but NMOSD remains as a rare disease. The differences in age- and sex-specific estimates highlight the importance of the serologic classification.Keywords
Funding Information
- Instituto de Salud Carlos III (CM14/00081 and CV15/00021)
- Instituto de Salud Carlos III (FIS 2015. PI15/00587)
- Instituto de Salud Carlos III (JR14/00016)
- Instituto de Salud Carlos III (RD16/0015/0002)
- Departament d'Innovaci�, Universitats i Empresa, Generalitat de Catalunya (SLT002/16/00354)
This publication has 18 references indexed in Scilit:
- Neuromyelitis optica spectrum disordersNeurology Neuroimmunology & Neuroinflammation, 2016
- Epidemiology of aquaporin‐4 autoimmunity and neuromyelitis optica spectrumAnnals of Neurology, 2016
- International consensus diagnostic criteria for neuromyelitis optica spectrum disordersNeurology, 2015
- Demographic and clinical features of neuromyelitis optica: A reviewMultiple Sclerosis Journal, 2015
- An Optimized Immunohistochemistry Technique Improves NMO-IgG Detection: Study Comparison with Cell-Based AssaysPLOS ONE, 2013
- The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United KingdomZeitschrift für Neurologie, 2013
- The prevalence of neuromyelitis optica in South East WalesEuropean Journal of Neurology, 2011
- A population-based study of neuromyelitis optica in CaucasiansNeurology, 2011
- An epidemiological study of neuromyelitis optica in CubaZeitschrift für Neurologie, 2009
- Revised diagnostic criteria for neuromyelitis opticaNeurology, 2006